Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS
· Delayed Price · Currency is USD
1.775
-0.005 (-0.28%)
Apr 17, 2025, 4:00 PM EDT
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $29.99M in the quarter ending December 31, 2024, with 18.96% growth. This brings the company's revenue in the last twelve months to $109.54M, down -5.34% year-over-year. In the fiscal year ending March 31, 2024, Medexus Pharmaceuticals had annual revenue of $113.05M with 4.59% growth.
Revenue (ttm)
109.54M
Revenue Growth
-5.34%
P/S Ratio
0.54
Revenue / Employee
1.34M
Employees
82
Market Cap
59.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
| Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
| Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
| Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
| Mar 31, 2020 | 55.51M | 21.64M | 63.91% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 210.49M |
| American Oncology Network | 1.76B |
Medexus Pharmaceuticals News
- 12 days ago - Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 5 weeks ago - Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp. - Newsfile Corp
- 7 weeks ago - Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 2 months ago - Medexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States - Newsfile Corp
- 2 months ago - Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada - Newsfile Corp
- 2 months ago - Medexus Schedules Third Fiscal Quarter 2025 Conference Call - Newsfile Corp
- 2 months ago - Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares - Newsfile Corp